Category CAR-T

PIER MARIA FORNASARI
2025-12-26

Johns Hopkins Scientists Develop Targeted Therapy for T-Cell Lymphomas and Leukemias

Researchers at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors. The therapy, an antibody-drug conjugate, targets a protein expressed on the surface of T-cell cancers to deliver a cancer cell-killing drug. The work, published Dec. 22 in Nature Cancer, provides

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-12-13

Roswell Park Study Shows IL-36 Gamma ‘Armored’ CAR T Cells Can Eradicate Solid Tumors

Team headed by Dr. Renier Brentjens finds reprogramming neutrophils is key to antitumor immune response  A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in their eradication. Led by Renier Brentjens, MD, PhD, Deputy Director and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-12-12

Oregon Health Science University study: CAR-T therapy shows long-term survival for patients with lymphoma

Five-year data from clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions in high-risk patients A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved CAR-T cell therapies offers long-term survival and potential cures for adult patients with relapsed or refractory large B-cell lymphoma, even

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-05-11

Enhanced CAR T cell therapy offers new strategy for lymphoma

Next-generation CAR T cell therapy works where other CAR T cell therapies have failed A next-generation “armored” CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments, including commercially available CAR T cell therapies. The new therapy diminished cancer in 81 percent of patients

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-05-07

New CAR T cell therapy benefits patients with advanced thyroid cancers

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, according to researchers from The University of Texas MD Anderson Cancer Center. Results from the first-in-human Phase I trial were presented today at the American Association

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-04-13

FDA clears IND for clinical trial testing switchable CAR-T therapy in patients with autoimmune diseases, without chemotherapy

Innovative cellular therapy has potential to treat patients with lupus, systemic sclerosis, myositis and RA without chemotherapy-induced immune suppression. Calibr-Skaggs Institute for Innovative Medicines, the drug discovery division of Scripps Research, announced today that the FDA has cleared their investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2025-02-01

CAR-T cells can transfer antitumour immunity to other T cells by exchanging surface proteins

Novel research in cells and mice models has provided insight into the mechanisms that regulate trogocytosis, a process during which immune cells can exchange membrane-bound proteins. The study showed that chimeric antigen receptor cells (so-called CAR-T cells) could transfer tumour antigen-specific receptors to recipient T cells, and in doing so equipped the latter cells with tumour-targeting

Read More

No Comments InCAR-T